Uterine Reaction to Oxytocin and Maternal-Neonatal Outcomes in Inducing Labor: A Retrospective Cohort Study

催产素引起的子宫反应及引产中母婴结局:一项回顾性队列研究

阅读:1

Abstract

BACKGROUND: Previous studies did not investigate the effect of gradually increasing the concentration of low-dose oxytocin on mother and newborn outcomes. The purpose of this study was to look at the relationship between oxytocin responsiveness and outcomes for both mothers and newborns during labor induction. METHODS: This retrospective cohort study was conducted at Nantong Maternal and Child Health Hospital, and participants were divided into the early reaction to oxytocin group and the later reaction to oxytocin group based on oxytocin response. Primary outcomes included Apgar score at 1 and 5 minutes, umbilical cord artery pH, neonatal intensive care unit admission, and postpartum hemorrhage. Secondary outcomes assessed the duration of labor. Multiple regression models were used to compare maternal and infant outcomes between the two groups. RESULTS: A total of 1803 participants were finally included in the statistical analysis, with 1083 in the early reaction to oxytocin group and 720 in the later reaction to oxytocin group. After adjusting for potential confounding factors, the risk of a lower 1-minute Apgar score (OR: 1.924, 95% CI: 1.012-3.655), an increased rate of neonatal intensive care unit admission (OR: 2.064, 95% CI: 1.150-3.703), and a higher incidence of postpartum hemorrhage were observed in the later reaction to oxytocin group (OR: 2.342, 95% CI: 1.631-3.361). Additionally, in this group, the first and second phases of labor were seen to be more drawn out (P<0.001, P<0.001). CONCLUSION: Later reaction to oxytocin was consistently associated with lower 1-minute Apgar scores, an increased number of admissions to neonatal intensive care units, a labor's first and second phases lasting a long time, and an increased occurrence of postpartum hemorrhage. These findings underscore the importance of identifying women who exhibit a delayed response to oxytocin in clinical practice. TRIAL REGISTRATION: The project was retrospectively registered with the Chinese Clinical Trial Registry (TRN: ChiCTR2100047137; 08/06/2021).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。